Dergiler / Turkish Journal of Biology / 2020 / Cilt: 44 - Sayı: 4

AKT-mediated phosphorylation of TWIST1 is essential for breast cancer cell metastasis

Sayfa
158–165
Yayın Tarihi
2020-08-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Our results indicate that phosphorylation of S42 and T125 by AKT is essential for TWIST1-mediated tumor growth and metastasis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Previously, it was shown that human TWIST1 (basic helix-loop-helix (b-HLH) is phosphorylated by Akt kinase at S42, T121, and S123.
📊
Temel Bulgular & Veri:To show in vivo effect of these phosphorylations, we created mouse TWIST1 expression vector and converted the codons of S42, T125, and S127 to unphosphorylatable alanine and phosphorylation mimicking Glutamic acid.
💡
Sonuç & Katkı:Our results indicate that phosphorylation of S42 and T125 by AKT is essential for TWIST1-mediated tumor growth and metastasis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:TWIST1 · breast cancer · metastasis

Abstract

Previously, it was shown that human TWIST1 (basic helix-loop-helix (b-HLH) is phosphorylated by Akt kinase at S42, T121, and S123. To show in vivo effect of these phosphorylations, we created mouse TWIST1 expression vector and converted the codons of S42, T125, and S127 to unphosphorylatable alanine and phosphorylation mimicking Glutamic acid. We hypothesized that alanine mutants would inhibit the metastatic ability of 4T1 cells while glutamic acid mutants would convert nonmetastatic 67NR cells into metastatic phenotype. To confirm this hypothesis, we created metastatic 4T1 and nonmetastatic 67NR cells expressing alanine mutants and glutamic acid mutants mouse TWIST1, respectively. Then, we injected 1 x 10(6) 67NR and 1 x 10(5) 4T1 cells overexpressing mutants of TWIST1 into the breast tissue of BALB/c mice. At the end of the 4th week, we sacrificed the animals, determined the numbers of tumors at lungs and liver. Although 67NR cells overexpressing wild-type TWIST1 did not show any metastasis, cells overexpressing S42E and T125E mutants showed 15-30 macroscopic metastasis to liver and lungs. Parallel to this, 4T1 cells expressing S42A and T125A mutants of TWIST1 showed no macroscopic metastasis. Our results indicate that phosphorylation of S42 and T125 by AKT is essential for TWIST1-mediated tumor growth and metastasis.

🔖

Bu Makaleye Atıf Yap

ERTOSUN, M. G., PEHLİVANOGLU, S., DİLMAC, S., TANRİOVER, G., OZES, O. N. (2020). AKT-mediated phosphorylation of TWIST1 is essential for breast cancer cell metastasis. Turkish Journal of Biology, Cilt: 44 - Sayı: 4, 158–165. https://ajindex.com/articles/201114

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Alexander NR, 2006, CANCER RES, V66, P3365, DOI 10.1158/0008-5472.CAN-05-3401 Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9 CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686 Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067 Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479 Connerney J, 2006, DEV DYNAM, V235, P1345, DOI 10.1002/dvdy.20717 ElGhouzzi V, 1997, NAT GENET, V15, P42. Elias MC, 2005,
  2. NEOPLASIA, V7, P824, DOI 10.1593/neo.04352 Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001 Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200 Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36 Kingston RE, 2003, CALCIUM PHOSPHATE TR, V20, P20 Kyo S, 2006, HUM PATHOL, V37, P431, DOI 10.1016/j.humpath.2005.12.021 Lee TK, 2006, CLIN CANCER RES, V12, P5369, DOI 10.1158/1078-0432.CCR-05-2722 Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712 Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144 Rice DPC, 2000,
  3. DEVELOPMENT, V127, P1845 Singh S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/215748 Wang DW, 2018, ONCOL REP, V39, P31, DOI 10.3892/or.2017.6076 Xu Y, 2017,
  4. ONCOGENE, V36, P1157, DOI 10.1038/onc.2016.286 Xu Y, 2013, AM J PATHOL, V183, P1281, DOI 10.1016/j.ajpath.2013.06.021 Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270 Yousfi M, 2002, BIOCHEM BIOPH RES CO, V297, P641, DOI 10.1016/S0006-291X(02)02260-X Zhang YQ, 2007,
  5. PATHOLOGY, V39, P470, DOI 10.1080/00313020701570053